{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-023999","form_type":"8-K","ticker":"RVPH","cik":"0001742927","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2023-08-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.065547+00:00","generated_at":"2026-06-11T07:46:56.597855+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Reviva completes enrollment in Phase 3 RECOVER study for brilaroxazine in schizophrenia; topline data expected Oct 2023","bullets":["Enrollment of 402 patients across US (~60%), Europe (~10%), and Asia (~30%) in pivotal Phase 3 RECOVER trial.","Topline efficacy and safety data for RECOVER expected in October 2023.","Over 50% of patients enrolled in 1-year open-label extension study; completion expected in Q3 2024.","Primary endpoint: change in PANSS total score from baseline to Day 28 vs placebo."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-023999","json":"https://secwatch.observer/filing/0001437749-23-023999.json","markdown":"https://secwatch.observer/filing/0001437749-23-023999.md","text":"https://secwatch.observer/filing/0001437749-23-023999.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1742927/000143774923023999/0001437749-23-023999-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1742927/000143774923023999/rvph20230816_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T07:46:56.597855+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}